

## SUPPLEMENTAL FIGURE LEGENDS

**Fig. S1.** ClustalW alignment of *Leishmania major* GCVP sequence (*Lm*) with sequences (GenBank sequence reference) from: *At*, *Arabidopsis thaliana* (GCVP2; CAA21210), *Dd*, *Dictyostelium discoideum* (XP\_637330), *Sp*, *Schizosaccharomyces pombe* (CAA91099), *Vc*, *Vibrio cholerae* (ZP\_00746488) and *Xl*, *Xenopus laevis* (AAH42245). N-terminal mitochondrial targeting peptides, predicted by TargetP, are shown by black letters on gray boxes. In the remainder of the sequence, degree of conservation of residues is indicated by increased background shading. Active-site residues are marked (#), with the catalytic lysine marked as (C). Residues predicted to interact with the H-protein are marked (\*).

**Fig. S2.** Growth of *L. major* WT FV1 and LV39 lines in RPMI-1% fetal bovine serum medium. A, *L. major* FV1; B, *L. major* LV39. Symbols: ●: RPMI including 285 µM L-serine; ○: RPMI without added serine (serum contains ~10 µM serine). Error bars indicate standard error of mean counts for triplicate cultures.

**Fig. S3.** Culture phenotype of *gcvP*- *Leishmania*. Growth in culture of WT, *gcvP*- and *gcvP*-/+*GCVP* parasites in RPMI media with 1% fetal calf serum and varied glycine and L-serine content. A, 133 µM glycine and 95 µM L-serine; B, 13 mM glycine and 95 µM L-serine; C, 133 µM glycine and 9.5 µM L-serine; D, As C, with 10 mM formate added. Symbols: ●: WT; □: *gcvP*-; ▲: *gcvP*-/+*GCVP* parasites. Error bars indicate standard deviation of mean counts for triplicate cultures.

SUPPLEMENTAL TABLE

Table S1. DNA primers used, listed in order cited in text.

Primer #	Sequence 5'-3' Purpose	Notes
B2057	cgaggatccacc <u>ATGCTCCGCCGTCTCCTCGCGTT</u> GCVP ORF PCR	BamHI site underlined. Non-coding nucleotides in lower case
B2062	ataggatcc <b>GAGCTCCGTTCGCTCTGTGGCTG</b> GCVP ORF PCR	SacI site in bold. Non-coding nucleotides in lower case
B2063	atacatatgaaa <b>GAGCTCATGCGTTACGCTCAGCATH</b> GCVP ORF PCR	SacI site in bold. Non-coding nucleotides in lower case
B2058	cacggatc <b>CTAGTAGAACTCCAATGGGGCACA</b> GCVP ORF PCR	BamHI site underlined. Non-coding nucleotides in lower case
B2137	AGCGTTGCCTTCGGGGTTCACAC PCR assay of gene disruption	
B2013	CCGTGGGCTTGTACTCGGTCA PCR assay of gene disruption	
B1675	GACGTCGGTGAGTTCAGGCT PCR assay of gene disruption	
B2184	GTGGTGATGGAGCGCTGTATGGAG Southern blot probe	
B2185	CTTGGTCAGACGCAGCACATACG Southern blot probe	
B2086	GAGGCTCACCGCGATGTCTG Amplifying end of GCVP minus stop codon	
B2497	ggaagaa <b>GATCTGTAGAACTCCAATGGGGCACACGAG</b> Amplifying end of GCVP minus stop codon	BglII site underlined. Non-coding nucleotides in lower case

## Figure S1 Scott et. al.

Lm : -----MLRRLLRVHGVFAPAG-----  
At : -----MERPLRLAYRGIVKRLVNDT-----  
Dd : -----MLKLLRNNGINKLKS-----  
Sp : -----MFRACSKLQYHGVTNLSRHL-----  
Vc : -----MTELILHS-----  
Xl : -----MQSCKSGVLSRALRLMPGRTMGCR-----

120 160 200 #####  
Lm : -----IADLMTTVLESIDLRTPLNNFKCLS-----  
At : -----DEQTHMAKFCGFHDIDSICATVEKSIRLDMSMKFSKFIA-----  
Dd : -----SLEQIYEYTIKDIRNLNRNLEENIEK-----  
Sp : -----DVPLPSVTRTPESQLWAFGSVNPNEKNPVNVS-----  
Vc : -----LCAUAAQTVQIRLEAPMQALAPA-----  
Xl : -----IEELIDKTVEGSIRIARPLKMDQV-----

240 280 320  
Lm : FQIMVTDTIKMDISNASLLEDTAAGECYLALNQHREK-RRKDFVSRDVFLS-----  
At : FQIVITDTGLEMNSASLLEDTAEEEAMACMCNINLKG-----  
Dd : FQIMVSEETGPLEMSNASLLEDTAEEEAMQCVMNISKSKGPFA-----  
Sp : YQTMIAADLTGISMNASLLEDTAAGEANVMLMANDRKK-----  
Vc : YQCMVMDLTAMEANASLLEDTAEEEAMALCQRAGKSK-----  
Xl : YQTMVCIDTGMVANASLLEDTAEEEAMQLCHRHNKRR-----

360 \* 400 \* # \* \* # 440  
Lm : KANGVCCAGVDLMASCLVKPAGMGADVVVGCA-----  
At : HANGVKVVMATDLLALTVLKPPGEFG-----  
Dd : HQANALVVAATDLSIALLKKPGW-----  
Sp : RSFMHMVVAATDLSIALLKSPG-----  
Vc : QANKLTVTATDLLASLVKAEGM-----  
Xl : HQGTLACCATTDLALCIMRPPG-----

480 520 560 600 640  
Lm : FYAIYHGEGLQCLAREIHQAKATFAVGMESLG-FSPVNNTYFDTLSFSMEEAPMTAADYQRCVERG-----  
At : MYAVYHGEGLASIAQRVHGLAGL-----  
Dd : MYAVYHCGQGIMDIANAVERKAI-----  
Sp : FYAIYHGEGLQBIANAYASTSELKSAE-----  
Vc : FYAVYHGEQGLRTIARRAHLT-----  
Xl : MFCVYHGEGLKHTARRVHNATVLAECIKRAG-----

680 # # # 760 # #  
Lm : ADIKQKLQCDITEMAACSOPNSGAQGEYAGLRIIRAYHESRG-----  
At : ENIGDLCITITGFLTSFOPNSGAQGEYAGLMI-----  
Dd : ESIISNMLCEVTGFLGQSCOPNSGAQGEYAGL-----  
Sp : EDIQQLMITTITGFLAACOPNSGAQGEYAGL-----  
Vc : EDIKQKLQCEITGYIAFSOPNSGAQGEYAGLVA-----  
Xl : QFEKDLCEITGYINISOPNSGAQGEYAGLA-----

# # 800 # # # C 840 880  
Lm : YDQDIRKLTSMVHEHGGCQYIDGANLNNAI-----  
At : YEEGIDELCNIIIBENGQVYMDGANMNA-----  
Dd : FEEGANDICDIIHANGQQVYMDGANMNA-----  
Sp : FPDVKEALEVIHGGQVYFDGANNMNA-----  
Vc : YEQQVREVCEMVHAAGGQVYLDGANMNA-----  
Xl : FEEDISNVCDLIIHKGNGQVYLDGANMNA-----

920 960 1000 1040 \* \* 1080  
Lm : ISIAFAWMLGSHGKTC-----  
At : ISATYIIPMMGSGGITDASKI-----  
Dd : ITYVYIPLKMGQGK-----  
Sp : ISWAYMMEPMGAGI-----  
Vc : ISWAYIIPMMGAKGK-----  
Xl : ISWAYIIPMMGAKGK-----

Figure S2 Scott et. al.




Figure S3 Scott et. al.

